Company
Agomab Therapeutics
- Biotech
- Location:
- Antwerp, Belgium
Description
Agomab Therapeutics develops disease-modifying therapies for fibro-inflammatory conditions through TGFβ/ALK5 (TGFβR1) pathway targeting, with a clinical pipeline using ontunisertib in fibrostenosing Crohn’s disease and AGMB-447 in idiopathic pulmonary fibrosis.
Agomab Therapeutics is located in the Belgium ecosystem.
Related
Herantis PharmaHerantis Pharma develops disease-modifying therapies designed to stop or reverse progression of neurodegenerative diseases, applying drug…
Enterprise TherapeuticsEnterprise Therapeutics researches and develops respiratory disease therapies, including inhaled ENaC blocker ETD001, to address mucus…
- Tandem TherapeuticsTandem Therapeutics develops Matrix Targeting Peptides that bind disease-associated extracellular matrix alterations, applying…
- AplagonAplagon develops a therapeutic called APAC, a vascular-injury targeting molecule that combines antiplatelet, anticoagulant, and…
SciRhomSciRhom develops humanized antibodies against iRhom2 that selectively inhibit TACE in immune cells, blocking TNF-alpha, IL-6, and HB-EGF…
BioArcticBioArctic develops therapeutics and related technologies for neurodegenerative disorders, focusing on disease-modifying treatments and…
Aphea.BioAphea.Bio develops microbial biostimulant and biocontrol products and pipelines for agriculture, delivering seed treatments, foliar…
ATXA TherapeuticsATXA Therapeutics develops selective small-molecule thromboxane receptor (TP) antagonists, including lead candidate NTP42, to treat…
LEO PharmaLEO Pharma develops and delivers innovative treatments for medical dermatology, producing medicines and supplying healthcare providers and…